ハイスループットスクリーニングの世界市場規模：技術別、用途別、製品・サービス別、地域別、範囲および予測

ハイスループットスクリーニングの市場規模と予測

ハイスループットスクリーニング市場規模は、2024年に232億6,000万米ドルと評価され、2024年から2031年にかけてCAGR 7.75%で成長し、2031年には400億4,000万米ドルに達すると予測されます。

ハイスループットスクリーニング（HTS）は、創薬やその他の研究分野において、特定の標的や条件に対して何千もの化合物、生物学的サンプル、遺伝物質を迅速に試験するために用いられる手法です。

この手法では、自動化技術を利用して多数のアッセイを同時に実施し、潜在的な薬剤候補や生物学的活性を効率的に同定することができます。HTSには通常、サンプルを迅速に処理・分析するために、ロボット工学、専用ソフトウエア、高度な検出システムが使用されます。

用途としては、HTSは主に製薬研究において、有効性、毒性、または特定の生物学的標的との相互作用について、化合物の大規模なライブラリーをスクリーニングすることにより、有望な薬剤候補を同定するために使用されています。

また、ゲノミクスやプロテオミクスにおいても、遺伝子の機能、タンパク質の相互作用、疾病メカニズムの研究に利用されています。さらにHTSは、化学物質がさまざまな生物系に与える影響を評価し、新しい農業用化合物を発見するために、環境科学や農業科学でも利用されています。

ハイスループットスクリーニングの世界市場力学

主な市場促進要因

創薬需要の高まり：新規かつ効果的な医薬品に対するニーズの高まりが、膨大な化合物ライブラリーから潜在的な医薬品候補を効率的に同定するハイスループットスクリーニング（HTS）の採用を後押ししています。米国食品医薬品局（FDA）によると、2023年現在、新薬開発にかかる平均コストは26億米ドルと推定され、最初の発見から市場承認までの期間は10～15年です。この高いコストと長い時間軸が、HTSのようなより効率的なスクリーニング手法の必要性を高めています。

自動化技術の進歩：ロボット工学と自動化技術の絶え間ない改善により、HTSプロセスの効率とスピードが向上し、大規模研究にとってより利用しやすく効果的なものとなっています。米国国立標準技術研究所（NIST）は2023年、ラボラトリーオートメーションの進歩により、HTSシステムの平均スループットが過去5年間で35％向上したと報告しています。

個別化医療への注目の高まり：個別化医療へのシフトに伴い、複雑な生物学的データを解析し、個々の患者に合わせた治療標的を特定するためのハイスループット手法が必要とされています。個別化医療連合（Personalized Medicine Coalition）の報告によると、2023年にFDAが承認する新薬の25%は個別化医療に分類され、2022年の20%から増加しました。

研究開発への投資の増加：生物医学研究と医薬品研究開発への資金と投資の増加は、HTS能力の拡大を支え、より包括的で多様なスクリーニングを可能にします。米国研究製薬工業協会（PhRMA）の報告によると、会員企業の2023年の研究開発投資額は推定1,023億米ドルで、2022年から7.5％増加しました。

バイオテクノロジーとゲノミクスの拡大：バイオテクノロジーとゲノミクス研究の拡大には、大規模なデータセットを処理し、治療開発の鍵となる遺伝的・分子的標的を特定するための高度なスクリーニング技術が必要です。例えば、2024年3月、Ginkgo Bioworksはゲノムデータ解析を統合した新しいHTSプラットフォームを発表し、治療応用の可能性のある遺伝子変異を1日当たり10万個以上スクリーニングできるようになった。

主な課題

複雑なデータ管理：HTSでは膨大な量のデータが生成されるため、その管理、解析、効果的な解釈には困難が伴う。このデータを扱うには、高度なソフトウエアと熟練した人材が必要で、リソースを大量に必要とします。

技術的限界と信頼性の問題：HTS技術は、アッセイの信頼性、感度、特異性の問題に直面する可能性があります。技術的限界は偽陽性や偽陰性を引き起こす可能性があり、スクリーニングプロセスの精度と効率に影響を与えます。

統合の課題：HTSシステムを既存の研究室のワークフローやデータ・インフラと統合することは、複雑で時間のかかることです。互換性の問題や広範なバリデーションの必要性は、シームレスな導入を妨げる可能性があります。

規制とコンプライアンスのハードル：厳しい規制要件と業界標準を遵守する必要性が、HTSプロセスを複雑にします。これらの規制へのコンプライアンスを確保することが、運用上の課題とコストに拍車をかける。

高い初期費用：高度なHTS装置の購入と維持に必要な多額の資本は、スクリーニングアッセイの開発と検証に関連するコストとともに、小規模の研究所や組織にとっては法外なものとなる可能性があります。

主要動向

人工知能と機械学習の統合：HTSにAIと機械学習を取り入れることで、データ分析と解釈が強化されます。これらの技術はスクリーニング結果の精度を向上させ、パターンやヒットの可能性をより効率的に特定し、データ処理に要する時間を短縮します。2023年の米国立衛生研究所（NIH）の報告書によると、創薬とHTSにおけるAIと機械学習の利用は2020年から2023年にかけて35％増加しました。この統合により、創薬スクリーニングキャンペーンにおける最初のヒット化合物同定に要する時間が40％短縮されました。

アッセイ技術の進歩：より高感度で特異的なアッセイの開発など、アッセイ技術の革新がHTSの能力を拡大しています。アッセイ法の開発により、生物学的標的をより詳細かつ信頼性の高い方法でスクリーニングできるようになり、より効果的な創薬・薬剤開発に貢献しています。プロメガ・コーポレーションは2023年12月に、タンパク質-タンパク質相互作用研究のために10倍の高感度を提供する、強化された生物発光レポーターアッセイを発売しました。

自動化とロボティクスの採用拡大：HTSシステムにおける自動化とロボティクスの増加は、スループットと効率の向上を推進しています。自動化されたプラットフォームは、スクリーニングプロセスを合理化し、人的ミスを減らし、より大量のサンプルの取り扱いを可能にすることで、より迅速で費用対効果の高い研究と発見を促進します。HighRes Biosolutionsは大手製薬企業と提携し、2024年1月に発表した適応スクリーニング用のAI駆動型ロボットシステムを開発しました。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 ハイスループットスクリーニング市場：技術別

• セルベースアッセイ
• ラボオンチップ（LOC）
• ラベルフリー技術
• 超高スループットスクリーニング（UHTS）

第5章 ハイスループットスクリーニング市場：用途別

• 創薬
• ターゲット同定
• 一次スクリーニング
• トキシコロジー

第6章 ハイスループットスクリーニング市場：製品・サービス別

• 機器
• 消耗品
• サービス
• ソフトウェア

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Rheon Automatic Machinery
• GEA Group
• Middleby Corporation
• Marel
• Bettcher Industries
• Gunther Maschinenbau GmbH
• Formax, Inc.
• Magurit Gefrierschneider GmbH
• Minerva Omega Group
• Metalbud NOWICKI

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

High Throughput Screening Market Size And Forecast

High Throughput Screening Market size was valued at USD 23.26 Billion in 2024 and is projected to reach USD 40.04 Billion by 2031, growing at a CAGR of 7.75% from 2024 to 2031.

High Throughput Screening (HTS) is a method used in drug discovery and other research fields to rapidly test thousands of compounds, biological samples, or genetic materials against specific targets or conditions.

This technique utilizes automated technologies to conduct a large number of assays simultaneously, enabling the efficient identification of potential drug candidates or biological activities. HTS typically involves robotics, specialized software, and sophisticated detection systems to process and analyze samples quickly.

In terms of application, HTS is predominantly used in pharmaceutical research to identify promising drug candidates by screening large libraries of compounds for their efficacy, toxicity, or interactions with specific biological targets.

It is also employed in genomics and proteomics to study gene function, protein interactions, and disease mechanisms. Additionally, HTS is utilized in environmental and agricultural sciences to assess the impact of chemicals on various biological systems and to discover new agricultural compounds.

Global High Throughput Screening Market Dynamics

The key market dynamics that are shaping the global high throughput screening market include:

Key Market Drivers

Rising Drug Discovery Demands: The increasing need for new and effective pharmaceuticals drives the adoption of High Throughput Screening (HTS) to efficiently identify potential drug candidates from vast compound libraries. According to the U.S. Food and Drug Administration (FDA), as of 2023, the average cost to develop a new drug was estimated at USD 2.6 Billion, with a timeline of 10-15 years from initial discovery to market approval. This high cost and long timeline drive the need for more efficient screening methods like HTS.

Advancements in Automation Technologies: Continuous improvements in robotics and automation technologies enhance the efficiency and speed of HTS processes, making them more accessible and effective for large-scale research. The National Institute of Standards and Technology (NIST) reported in 2023 that advancements in laboratory automation have increased the average throughput of HTS systems by 35% over the past five years.

Growing Focus on Personalized Medicine: The shift towards personalized medicine necessitates high-throughput methods to analyze complex biological data and identify tailored therapeutic targets for individual patients. The Personalized Medicine Coalition reported that 25% of all new drugs approved by the FDA in 2023 were classified as personalized medicines, up from 20% in 2022.

Increased Investment in Research and Development: Growing funding and investment in biomedical research and pharmaceutical R&D support the expansion of HTS capabilities, enabling more comprehensive and diverse screening efforts. The Pharmaceutical Research and Manufacturers of America (PhRMA) reported that its member companies invested an estimated $102.3 billion in R&D in 2023, up 7.5% from 2022.

Expansion of Biotechnology and Genomics: The rise in biotechnology and genomics research requires advanced screening technologies to handle large datasets and identify key genetic and molecular targets for therapeutic development. For instance, in March 2024, Ginkgo Bioworks unveiled a new HTS platform integrating genomic data analysis, capable of screening over 100,000 genetic variants per day for potential therapeutic applications.

Key Challenges:

Complex Data Management: HTS generates vast amounts of data that can be challenging to manage, analyze, and interpret effectively. Handling this data requires sophisticated software and skilled personnel, which can be resource-intensive.

Technical Limitations and Reliability Issues: HTS technologies may face issues with assay reliability, sensitivity, and specificity. Technical limitations can lead to false positives or negatives, impacting the accuracy and efficiency of the screening process.

Integration Challenges: Integrating HTS systems with existing laboratory workflows and data infrastructure can be complex and time-consuming. Compatibility issues and the need for extensive validation can hinder seamless implementation.

Regulatory and Compliance Hurdles: The need to adhere to stringent regulatory requirements and industry standards can complicate the HTS process. Ensuring compliance with these regulations adds to the operational challenges and costs.

High Initial Costs: The significant capital required for purchasing and maintaining advanced HTS equipment, along with the costs associated with developing and validating screening assays, can be prohibitive for smaller laboratories and organizations.

Key Trends

Integration of Artificial Intelligence and Machine Learning: The incorporation of AI and machine learning into HTS is enhancing data analysis and interpretation. These technologies improve the accuracy of screening results, identify patterns and potential hits more efficiently, and reduce the time required for data processing. According to a report by the National Institutes of Health (NIH) in 2023, the use of AI and machine learning in drug discovery and HTS increased by 35% from 2020 to 2023. This integration has led to a 40% reduction in the time required for initial hit identification in drug screening campaigns.

Advancements in Assay Technologies: Innovations in assay technologies, such as the development of more sensitive and specific assays, are expanding the capabilities of HTS. Enhanced assay methods allow for more detailed and reliable screening of biological targets, contributing to more effective drug discovery and development. Promega Corporation launched an enhanced bioluminescent reporter assay in December 2023, offering 10 times higher sensitivity for protein-protein interaction studies.

Growing Adoption of Automation and Robotics: Increased automation and robotics in HTS systems are driving higher throughput and efficiency. Automated platforms streamline the screening process, reduce human error, and enable the handling of larger sample volumes, facilitating faster and more cost-effective research and discovery. HighRes Biosolutions partnered with a leading pharmaceutical company to develop an AI-driven robotic system for adaptive screening, announced in January 2024.

Global High Throughput Screening Market Regional Analysis

Here is a more detailed regional analysis of the global high throughput screening market:

North America

North America dominating the global high throughput screening (HTS) market, driven by its advanced research infrastructure and strong focus on innovation in pharmaceuticals and biotechnology. The United States and Canada are at the forefront of adopting and integrating HTS technologies, leveraging their well-established R&D ecosystem and significant investments in cutting-edge research.

Several key factors contribute to North America's dominance in the HTS market. The region's robust pharmaceutical and biotechnology industries drive demand for efficient drug discovery and development processes, supported by substantial funding and a strong pipeline of research projects. Additionally, North America's well-developed infrastructure, including leading research institutions and pharmaceutical companies, further fuels the growth of HTS technologies.

In North America, notable trends include the increasing integration of artificial intelligence and machine learning into HTS processes to enhance data analysis and predictive capabilities. There is also a growing emphasis on personalized medicine, leading to more sophisticated and tailored screening assays. Furthermore, advancements in automation and robotics are streamlining HTS workflows, boosting efficiency, and enabling higher throughput in drug discovery and development.

Asia Pacific

Asia-Pacific, with China as a key player, is witnessing rapid growth in the High Throughput Screening (HTS) market. The region's expanding biotechnology and pharmaceutical sectors are driving the adoption of advanced HTS technologies, positioning Asia-Pacific as a significant and fast-growing market for screening solutions.

The rapid growth of the HTS market in Asia-Pacific is driven by several factors. In China, substantial investments in pharmaceutical research and biotechnology are fueling demand for efficient drug discovery tools. Additionally, the region's expanding research infrastructure, increasing focus on personalized medicine, and supportive government policies contribute to the accelerated adoption of HTS technologies.

Key trends in the Asia-Pacific HTS market include the rising integration of advanced automation and robotics to enhance screening efficiency and throughput. There is also a growing emphasis on developing and utilizing novel screening assays to support complex drug discovery processes. Furthermore, increasing collaborations between regional research institutions and global pharmaceutical companies are driving innovation and expanding the reach of HTS technologies across the region.

Global High Throughput Screening Market: Segmentation Analysis

The Global High Throughput Screening Market is Segmented on the basis of Technology, Application, Product & Service, And Geography.

High Throughput Screening Market, By Technology

• Cell-Based Assays
• Lab-on-a-Chip (LOC)
• Label-Free Technology
• Ultra-High-Throughput Screening (UHTS)

Based on Technology, the Global High Throughput Screening Market is bifurcated into Cell-Based Assays, Lab-on-a-Chip (LOC), Label-Free Technology, Ultra-High-Throughput Screening (UHTS). The cell-based assay technology is projected to lead the market during the forecast. This dominance is primarily due to the ability of this technology to generate multiple biologically relevant data. Also, the assessing compound attributes is another factor projected to enhance the application of cell-based assay.

High Throughput Screening Market, By Application

• Drug Discovery
• Target Identification
• Primary Screening
• Toxicology

Based on Application, the Global High Throughput Screening Market is bifurcated into Drug Discovery, Target Identification, Primary Screening, and Toxicology. In the high throughput screening (HTS) market, cell-based assays are currently dominating due to their broad applicability in drug discovery and biological research. These assays are essential for evaluating cellular responses to various compounds and are widely used across pharmaceutical and biotechnology industries. Conversely, Label-Free Technology is the rapidly growing segment, driven by its ability to provide real-time, non-invasive measurements without the need for labels or dyes. This technology offers advantages such as reduced assay complexity and improved accuracy, contributing to its increasing adoption and rapid growth in the HTS market.

High Throughput Screening Market, By Product & Service

• Instruments
• Consumables
• Services
• Software

Based on Product & Service, the Global High Throughput Screening Market is bifurcated into Instruments, Consumables, Services, and Software. In the high throughput screening (HTS) market, instruments are the dominating segment, as they form the backbone of HTS systems, enabling the automation and high-throughput capabilities necessary for large-scale screening processes. The demand for sophisticated and high-performance HTS instruments drives this segment's leading position. Meanwhile, software is the rapidly growing segment, fueled by advancements in data analytics, machine learning, and artificial intelligence. Enhanced software solutions for data management and analysis are becoming increasingly vital for interpreting complex screening results and improving overall HTS efficiency, contributing to its swift growth.

High Throughput Screening Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global High Throughput Screening Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In the high throughput screening (HTS) market, North America is the dominating region, driven by its advanced research infrastructure, strong pharmaceutical and biotechnology sectors, and significant investments in cutting-edge HTS technologies. The region's established market presence and extensive R&D activities contribute to its leading position. Conversely, Asia Pacific is the rapidly growing region, with China and other countries in the area experiencing substantial growth due to increasing investments in research and development, expanding pharmaceutical industries, and the adoption of advanced HTS technologies. This region's rapid industrialization and focus on innovation are fueling its swift expansion in the HTS market.

Key Players

The "Global High Throughput Screening Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Rheon Automatic Machinery, GEA Group, Middleby Corporation, Marel, Bettcher Industries, Formax, Inc., Magurit Gefrierschneider GmbH, Minerva Omega Group, Metalbud NOWICKI.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global High Throughput Screening Market Recent Developments
• In October 2023, Thermo Fisher Scientific launched the new Orbitrap Exploris 120 Mass Spectrometer, designed to enhance high-throughput screening capabilities with superior sensitivity and accuracy for drug discovery applications.
• In November 2023, PerkinElmer introduced its upgraded Chemagic 360 automated sample preparation system, which integrates advanced robotics for streamlined high-throughput screening workflows in genomics and proteomics research.
• In December 2023, Agilent Technologies released a next-generation open-access high-throughput screening platform, featuring enhanced data analytics tools and a more flexible assay environment to accelerate drug development.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. High Throughput Screening Market, By Technology

• Cell-based Assays
• Lab-on-a-Chip (LOC)
• Label-free Technology
• Ultra-high-throughput Screening (UHTS)

5. High Throughput Screening Market, By Application

• Drug Discovery
• Target Identification
• Primary Screening
• Toxicology

6. High Throughput Screening Market, By Product & Service

• Instruments
• Consumables
• Services
• Software

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Rheon Automatic Machinery
• GEA Group
• Middleby Corporation
• Marel
• Bettcher Industries
• Gunther Maschinenbau GmbH
• Formax, Inc.
• Magurit Gefrierschneider GmbH
• Minerva Omega Group
• Metalbud NOWICKI

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References